FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1

On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda, Merck & Co., Inc., Whitehouse Station, NJ) for the treatment of patients with recurrent, locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenoca...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Fashoyin‐Aje, Lola, Donoghue, Martha, Chen, Huanyu, He, Kun, Veeraraghavan, Janaki, Goldberg, Kirsten B., Keegan, Patricia, McKee, Amy E., Pazdur, Richard
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324629/
https://ncbi.nlm.nih.gov/pubmed/30120163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0221
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares